PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Org Lett. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2808138
NIHMSID: NIHMS162953

Glycosylated PROLI/NO Derivatives as Nitric Oxide Prodrugs

Abstract

An external file that holds a picture, illustration, etc.
Object name is nihms162953f6.jpg

GlcNAc-PROLI/NO prodrugs that are activated by N-acetylglucosaminidase to release nitric oxide (NO) are described. A classical acid-amine coupling is used to bi-functionalize these PROLI/NO prodrugs, which on activation generate up to 4 moles of NO, a peptide residue and an N-acetylglucosamine residue. Many of the prodrugs synthesized are efficient sources of intracellular NO.

Nitric oxide (NO) plays a vital role in many physiological processes such as blood pressure regulation, platelet aggregation, immune response, and neurotransmission.1 Hence, NO-releasing drug development is emerging as a promising area.2 Amongst different NO donors, diazeniumdiolate anions are reliable and efficient sources of NO. These compounds under physiological conditions release up to 2 molar equivalents of NO, with well-defined half-lives varying from 2 s to 20 h.3 Diazeniumdiolate anions are often transformed to O2-substituted derivatives (diazeniumdiolate prodrugs), which upon activation by a metabolic trigger or hydrolysis generate NO through the intermediacy of the parent anion. This prodrug approach helps in site-directed delivery of NO. The literature is replete with examples of diazeniumdiolate prodrugs that are activated by glutathione,4 cytochrome P450,5 and esterases.6 Although many of these prodrugs have significant biological activities and efficiently release NO on activation, they also form secondary amines and cleaved protecting groups that may not always be biocompatible and nontoxic (Figure 1).

Figure 1
Diazeniumdiolate prodrugs releasing NO and potentially non-biocompatible metabolites on activation.

Our goal was to design, synthesize and evaluate diazeniumdiolate prodrugs that can be metabolically activated to efficiently release NO and whose degradation products are normal mammalian metabolites. These prodrugs could have potential applications in targeting NO for therapeutic benefit and could also be excellent research tools to study NO-dependent signaling mechanisms.

O2-Glycosylated diazeniumdiolates79 (Figure 1, R = sugar residue), upon activation by corresponding glycosidases, produce NO, a sugar, and a secondary amine. For example, O2-glycosylated PYRRO/NO compounds would generate NO, the cleaved sugar unit, and pyrrolidine (Figure 2). While the glycoside protecting group released should not be toxic to the host, the secondary amine (pyrrolidine) generated may have toxic effects.

Figure 2
O2-glycosylated PYRRO/NO, O2-glycosylated PROLI/NO and their corresponding metabolites on activation.

The diazeniumdiolate of proline (PROLI/NO),10 on decomposition, forms NO and proline, which is a natural amino acid and biocompatible metabolite. Thus, O2-glycosylated PROLI/NO prodrugs on degradation would form proline, NO, and a sugar (Figure 2). Morever, PROLI/NO has a carboxylic acid functional group that can be synthetically manipulated for future drug development, including increased payload of NO.

Glucose was the first choice amongst all possible sugar protective groups due its status as an inexpensive and commercially available substrate for glycosylation. Thus O2-glucosylated-PROLI/NO peracetate was synthesized using a reported protocol.11 Interestingly, the literature suggests that esters of PROLI/NO prodrugs have better cell permeability than their free carboxylic acid counterparts.12 The cell permeabilities are determined by comparing intracellular NO release by the compounds using the nitric oxide-sensitive fluorophore, 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM diacetate).13 Accordingly, the O2-glucosylated-PROLI/NO peracetate was transformed to its methyl ester, which was further deacetylated (see Supporting Information for details). However, to our surprise, O2- glucosylated-PROLI/NO peracetate11, its methyl ester and O2-glucosylated-PROLI/NO methyl ester (deacetylated derivative) did not show a significant amount of intracellular NO release by DAF-FM assay (data in Supporting Information). This indicated that either the prodrugs were not cell-permeable or they were not activated intracellularly to release NO during the course of the experiment. Thus, our strategy to develop cell permeable and biocompatible nitric oxide donors had to be revised. A recent report from our group demonstrated that N-acetylglucosamine (GlcNAc)-protected diazeniumdiolate prodrugs are activated by their corresponding N-acetylglucosaminidase.9 Therefore, we envisaged GlcNAc-PROLI/NO and its analogues as cell-permeable and biocompatible NO donor candidates.

The synthesis of GlcNAc-PROLI/NO began with the treatment of an acetone solution of 1-chloro-N-acetylglucosamine triacetate to the previously reported compound 111 to give 2 in 38% yield (Scheme 1). The primary alcohol was oxidized by a modified Sharpless protocol (ruthenium trichloride and sodium periodate) to afford GlcNAc-PROLI/NO peracetate 3 in 49% yield. The deacetylation of 3 using 3 equivalents of sodium methoxide in methanol gave GlcNAc-PROLI/NO 4. Both the compounds 3 and 4 were converted to their methyl esters 5 and 6, respectively, using diazomethane in ether in good yields (Scheme 1).

Scheme 1
Synthesis of GlcNAc-PROLI/NO derivatives.

The next task was to bi-functionalize the PROLI/NO prodrug, with the aim of generating up to 4 moles of NO, thus doubling the theoretical payload. The classical carboxylic acid and amine coupling was the first choice to be explored. There are several coupling agents commercially available to execute such coupling reactions.14 The coupling of 3 and ethylenediamine was accomplished with O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), 1-hydroxy-7-azabenzotriazole (HOAt), and Hünig’s base (DIPEA) to afford 7 in 55% yield. Compound 7 was deacetylated in 62% yield to afford 8 (Scheme 1). Furthermore, the ethylenediamine, a non-natural amine linker, was replaced with the naturally occurring diamine, L-lysine. The carboxylic acid in lysine could be advantageous as a synthetic handle for further drug development.11 The desired bivalent peracetate 9 was synthesized by reaction between acid 3 and lysine methyl ester dihydrochloride using the protocol developed for compound 7. Removal of the acetyl protection of 9 furnished the bis-PROLI/NO with lysine methyl ester linker 10 in 69% yield (Scheme 1). The methyl ester may generate methanol which can be toxic to the cells. However, the methyl ester derivatives can be replaced by the ethyl counterparts, to overcome any methanol-related toxicity in future investigations.

To demonstrate the generality of this approach we replaced the PROLI/NO moiety of these prodrugs by SARCO/NO (Figure 1, R1, = CH2CO2-H; R2 = Me; R = Na). GlcNAc-SARCO/NO, when metabolized, would produce sarcosine (N-methyl glycine) along with GlcNAc and NO. Sarcosine is a non-toxic amino acid found in muscles and other tissues and is often used in manufacturing biodegradable surfactants and toothpaste.15 The synthesis began with 1116 and involved reaction conditions similar to those of their PROLI/NO counterparts resulting in comparable yields (Scheme 2). Efforts are underway to synthesize the bis-GlcNAc-SARCO/NO derivatives with different linkers.

Scheme 2
Synthesis of GlcNAc-SARCO/NO compounds

The N-acetylglucosaminidase-activated NO release was determined by chemiluminescence assay. Compounds 4, 6, 14 and 16 are expected to release 2 moles of NO per mole of compound. Compound 6 displayed quantitative NO release over the period of experiment (ca. 60-min), whereas the compounds 4, 14 and 16 displayed between 50% to 75% NO-release (Table 1). The bivalent compounds 8 and 10 are expected to generate 4 moles of NO. Compounds 8 and 10 released 88% and 82%, respectively, of NO on activation by N-acetylglucosaminidase. Thus, the chemiluminescence assay using commercially available N-acetylglucosaminidase is a proof of concept for the hypothesis of enzymatic activation to release NO.17

Table 1
Extent of NO generation on hydrolysis of compounds under catalysis by N-acetylglucosaminidase isolated from jack bean.

The ability of these prodrugs to deliver NO intracellularly was determined by DAF-FM assay on normal human skin fibroblast BJ-5ta cells. Most of the compounds synthesized were tested for DAF-FM activity to evaluate their intracellular NO release. Some of the compounds displayed significant NO release over the control, highlighting their potential to deliver intracellular NO (Figure 3). However, a few compounds displayed DAF fluorescence comparable to that of the control (data for these compounds are not shown in Figure 3), indicating that either these compounds are not cell permeable or the cells are not equipped to activate these compounds to release NO during the course of the experiment. The intracellular NO release during the course of experiment by compound 5 was noteworthy, and may be the result of its very high cell permeability and/ or fast hydrolysis to release NO. Efforts are underway to reveal the mechanistic origin of this high intracellular NO release by compound 5.

Figure 3
Levels of intracellular nitric oxide formation upon treatment of BJ-5ta cells with compounds (100 µM final concentration) and DMSO (control) as determined by DAF-FM diacetate fluorescence study.

Thus, a series of novel GlcNAc-PROLI/NO compounds were synthesized. The synthetic strategy developed was successfully extended to prepare the SARCO/NO analogues and can, in principle, be further extended to tether these compounds to a variety of dendrimers, fluorescent tags, or peptides for future drug development. These GlcNAc compounds upon activation by jack bean enzyme efficiently released NO. The bis-PROLI/NO conjugates doubled NO payload accompanied by plausibly biocompatible metabolites. The DAF-FM assay conducted on normal cells demonstrated cell permeability and their ability to generate intracellular NO. Two previously reported O2-glycosylated diazeniumdiolate prodrugs are lead anti-leishmanial compounds.9 Efforts are underway to arrange further biological screening of the new Glc-NAc compounds.

Supplementary Material

1_si_001

Acknowledgment

This project has been funded with Federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. We are grateful to Ms. Susan Kenney, NCI-Frederick Screening Technology Branch, for providing us cell line.

Footnotes

Supporting Information Available: Preparative and cell culture procedures, analytical data, and NMR spectra for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

References

1. (a) Ignarro LJ. Angew. Chem., Int. Ed. 1999;38:1882–1892. (b) Furchgott RF. Angew. Chem., Int. Ed. 1999;38:1870–1880. (c) Moncada S, Palmer RMJ, Higgs EA. Pharmacol. Rev. 1991;43:109–142. [PubMed]
2. (a) Miller MR, Megson IL. Brit. J. Pharmacol. 2007;151:305–321. [PubMed] (b) Wang PG, Xian M, Tang X, Wu X, Wen X, Cai T, Janczuk AJ. Chem. Rev. 2002;102:1091–1134. [PubMed] (c) Megson IL, Webb DJ. Expert Opin. Investig. Drugs. 2002;11:587–601. [PubMed]
3. Hrabie JA, Keefer LK. Chem. Rev. 2002;102:1135–1154. [PubMed]
4. Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK. Mol. Cancer Ther. 2003;2:409–417. [PubMed]
5. Saavedra JE, Billiar TR, Williams DL, Kim Y-M, Watkins SC, Keefer LK. J. Med. Chem. 1997;40:1947–1954. [PubMed]
6. Saavedra JE, Shami PJ, Wang LY, Davies KM, Booth MN, Citro ML, Keefer LK. J. Med. Chem. 1999;43:261–269. [PubMed]
7. Showalter BM, Reynolds MM, Valdez CA, Saavedra JE, Davies KM, Klose JR, Chmurny GN, Citro ML, Barchi JJ, Jr, Merz SI, Meyerhoff ME, Keefer LK. J. Am. Chem. Soc. 2005;127:14188–14189. [PubMed]
8. (a) Cai TB, Lu D, Landerholm M, Wang PG. Org. Lett. 2004;6:4203–4205. [PubMed] (b) Wu X, Tang X, Xian M, Wang PG. Tetrahedron Lett. 2001;42:3779–3782.
9. Valdez CA, Saavedra JE, Showalter BM, Davies KM, Wilde TC, Citro ML, Barchi JJ, Jr, Deschamps JR, Parrish D, El-Gayar S, Schleicher U, Bogdan C, Keefer LF. J. Med. Chem. 2008;51:3961–3970. [PMC free article] [PubMed]
10. Saavedra JE, Southan GJ, Davies KM, Lundell A, Markou C, Hanson SR, Adrie C, Hurford WE, Zapol WM, Keefer LK. J. Med. Chem. 1996;39:4361–4365. [PubMed]
11. Chakrapani H, Showalter BM, Kong L, Keefer LK, Saavedra JE. Org. Lett. 2007;9:3409–3412. [PubMed]
12. Chakrapani H, Maciag AE, Citro ML, Keefer LK, Saavedra JE. Org. Lett. 2008;10:5155–5158. [PubMed]
13. Wardman F. Free Radical Biol. Med. 2007;43:995–1022. [PubMed]
14. Han S-Y, Kim Y-A. Tetrahedron. 2004;60:2447–2467.
15. Lanigan RS. Int. J. Toxicol. 2001;20:1–14. [PubMed]
16. Nguyen J-T, Velazquez CA, Knaus EE. Bioorg. Med. Chem. 2005;13:1725–1738. [PubMed]
17. Concentration of the activating enzyme has an important role in NO yield. However, it is difficult to determine exactly which enzyme, including concentration, is involved for the activation of these prodrugs inside the cell. Hence, the chemiluminescence assay and intracellular NO-release by DAF-FM assay may have different NO yields.